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Abstract
Introduction: Polycystic ovary syndrome (PCOS) is associated with an increasing number of metabolic comorbidities. About 50% of PCOS 
patients are obese, and insulin resistance affects up to 70% of these women. The endocannabinoid system contributes to human energy 
homeostasis. CNR1 is a biological candidate for human obesity and related metabolic disorders. The aim of this study was to determine 
the relationships between CNR1 polymorphisms and anthropometric and metabolic parameters in PCOS women. 
Material and methods: 130 women diagnosed with PCOS according to the Rotterdam criteria were recruited. The control group consisted 
of 70 healthy women. Medical history was taken, and physical examination as well as assessment of anthropometric (body mass, height, 
waist and hip circumference, BMI, waist-to-hip ratio [WHR]) and metabolic parameters (glucose and insulin, the insulin resistance index 
HOMA, lipid profile) was carried out. Genetic studies to detect six CNR1 gene polymorphisms were performed. 
Results: The total cholesterol and low-density lipoprotein (LDL) cholesterol levels in PCOS women carrying T/T genotype of rs2023239 
CNR1 polymorphism were higher than in those with C/T and C/C. There were no statistical differences in other metabolic parameters or 
in the value of BMI and WHR between the variants of rs2023239 CNR1 polymorphism. The other studied polymorphisms of the CNR1 
gene were not associated with anthropometric or metabolic parameters in PCOS women. There were no differences in anthropometric 
or metabolic parameters between the variants of studied polymorphisms of the CNR1 gene in control women. 
Conclusions: On the basis of our study, it seems that CNR1 polymorphisms are not associated with obesity and metabolic disorders, 
including insulin resistance, in PCOS women. (Endokrynol Pol 2014; 65 (3): 181–188)
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Streszczenie
Wstęp: Zespół wielotorbielowatych jajników wiąże się z licznymi zaburzeniami metabolicznymi. Około 50% kobiet z PCOS jest otyłych, 
a insulinooporność wykazuje do 70% kobiet z tym zespołem. Układ endokanabinoidowy odgrywa rolę w regulacji równowagi energe-
tycznej organizmu. Gen CNR1 jest genem kandydatem związanym z otyłością i zaburzeniami metabolicznymi. Celem badania była ocena 
wzajemnych powiązań między polimorfizmami genu CNR1 a parametrami antropometrycznymi i metabolicznymi u pacjentek z PCOS.
Materiał i metody: Do badania włączono 130 kobiet, u których w oparciu o kryteria rotterdamskie postawiono rozpoznanie PCOS. Grupę 
kontrolną stanowiło 70 zdrowych kobiet. U wszystkich badanych przeprowadzono wywiad lekarski, badanie fizykalne z oceną para-
metrów antropometrycznych (masa i wysokość ciała, obwód talii i bioder, indeks masy ciała, wskaźnik talia–biodra), wykonano badania 
biochemiczne (ocena stężeń glukozy i insuliny, wskaźnika insulinooporności HOMA, lipidogramu). Przeprowadzono również badania 
genetyczne oceniające sześć polimorfizmów genu CNR1.
Wyniki: Stężenie cholesterolu całkowitego i cholesterolu frakcji LDL było wyższe u kobiet z PCOS i genotypem T/T polimorfizmu rs2023239 
genu CNR1 w porównaniu z pacjentkami z genotypami C/T i C/C. Nie było istotnych statystycznie różnic dotyczących innych parame-
trów metabolicznych (stężenia glukozy, insuliny, wskaźnik HOMA) ani wskaźników masy ciała i talia–biodra między poszczególnymi 
genotypami polimorfizmu rs2023239. Nie wykazano zależności pomiędzy innymi badanymi polimorfizmami genu CNR1 a parametrami 
antropometrycznymi i metabolicznymi u pacjentek z PCOS. Nie stwierdzono również takich zależności u kobiet z grupy kontrolnej.
Wnioski: Na podstawie przedstawionego badania wydaje się, że polimorfizmy genu CNR1 nie są związane z otyłością ani zaburzeniami 
metabolicznymi, w tym insulinoopornością, u kobiet z PCOS. (Endokrynol Pol 2014; 65 (3): 181–188)
Słowa kluczowe: zespół wielotorbielowatych jajników; układ endokanabinoidowy; polimorfizm genu CNR1 
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Introduction
Polycystic ovary syndrome (PCOS) is among the most 
commonly diagnosed endocrine diseases in women of 
reproductive age. It is characterised by hyperandrogen-
ism, abnormalities in gonadotropin secretion, chronic 
anovulation and polycystic ovaries [1, 2]. PCOS patients 
have more metabolic disturbances than the general 
population and are at increased risk of developing 
type  2 diabetes [3–5] and cardiovascular disease [6]. 
About 50% of PCOS patients are obese, while insulin 
resistance and hyperinsulinaemia affect up to 70% 
of women with this syndrome [7]. Abnormalities in 
carbohydrate metabolism in PCOS patients include 
abnormal glucose tolerance as well as type 2 diabetes 
[8] and in lipid metabolism decreased levels of high-
density lipoprotein (HDL) cholesterol and increased 
LDL cholesterol and triglycerides [9]. The prevalence 
of metabolic syndrome in patients with PCOS ranges 
from 33.4% to 47%. There is evidence of an increased 
incidence of hypertension in PCOS patients [10–12]. 
The endocannabinoid system contributes to hu-
man energy homeostasis and plays a role in lipid and 
carbohydrate metabolism and also in fat accumulation 
in liver and muscles [13–16]. Its key factors are the can-
nabinoid receptors that are expressed in a variety of 
tissues including the adipose tissue, liver, skeletal mus-
cle, brain, gastrointestinal tract and pancreas [17]. The 
cannabinoid receptor 1 gene (CNR1), which encodes 
the cannabinoid receptor, is a biological candidate for 
human obesity and related metabolic disorders and is 
located on chromosome 6 (6q14-q15). There is evidence 
about the higher activation of the endocannabinoid 
system in obese people and animals and higher expres-
sion of CNR1 in visceral adipose tissue [18]. There are 
some studies investigating the relationships between 
common variants of CNR1 and obesity as well as 
metabolic disturbances, but the results of these studies 
are conflicting. In one study, carriers of 3813G variant 
of CNR1 had central distribution of fatty tissue and 
general high accumulation of adipose tissue [19,20]. In 
another study, A3813G polymorphism was related to 
higher waist circumference and G1422A polymorphism 
was associated with higher waist circumference and 
higher value of waist-to-hip ratio [21]. In our previous 
study, we found relationships between various CNR1 
polymorphisms and obesity in postmenopausal women 
[22]. However, there have also been some studies find-
ing no associations between CNR1 polymorphisms and 
obesity [23–26].
To date, there is no evidence about the CNR1 poly-
morphisms in women with PCOS. These correlations 
are especially interesting because metabolic distur-
bances are common in PCOS women and, on the other 
hand, the endocannabinoid system not only plays a role 
in metabolic aspects of body weight, but also influences 
the hypothalamic-pituitary axis and function of gonads 
[27, 28]. Demonstration of the association between 
CNR1 polymorphisms and metabolic disorders could 
enable the early identification of women with PCOS 
particularly at risk of those metabolic abnormalities. 
Then the targeted therapy of medicines modifying the 
activity of the CNR1 receptor would be possible. The 
aim of our study was to investigate the influence of 
various CNR1 polymorphisms on anthropometric and 
metabolic parameters in PCOS women.
Material and methods
The study included 130 patients with PCOS (mean 
± SD age: 24.91 ± 4.85 years, BMI: 26.96 ± 6.96 kg/m2) 
diagnosed in the Department of Endocrinology, Diabe-
tology and Isotope Treatment in the Medical University 
of Wroclaw. PCOS was diagnosed according to the 
Rotterdam consensus: two out of three criteria should 
be met: 1) oligomenorrhoea or amenorrhea (menstrual 
periods that occur at intervals of greater than 35 days or 
the absence of menstruation greater than six months); 
2) clinical and/or biochemical hyperandrogenism (hir-
sutism on the Ferriman-Gallwey scale, score > 8 or high 
free androgen index > 7%); and 3) characteristic image 
of polycystic ovaries on gynaecological ultrasound (ova-
ries featuring either ten or more follicles measuring 2–9 
mm in diameter or their volume greater than 10 cm3). 
Patients with hypercortisolemia, hyperprolactinemia, 
impaired thyroid function, or suspicion of ovarian or 
adrenal tumour were excluded from the study. The 
control group consisted of 70 healthy women (mean 
± SD age: 24.90 ± 4.25 years, BMI: 25.71 ± 6.27 kg/m2). 
Patients eligible for the study stated that during the 
three months prior to the study they had not been on 
any special diet or practiced intense physical exercise, 
had consumed alcohol occasionally, and had smoked no 
more than five cigarettes a day. The study protocol was 
approved by the Ethics Committee of Wroclaw Medi-
cal University and all the subjects gave their informed 
consent in writing.
In all the subjects, the following were carried out:
 — medical history and physical examination; 
 — assessment of anthropometric parameters (body 
mass, height, waist and hip circumference, BMI, 
WHR);
 — evaluation of hormonal parameters (testosterone, 
sex hormone-binding globulin [SHBG], androstene-
dione, luteinising hormone [LH], follicle-stimulating 
hormone [FSH]);
 — assessment of metabolic parameters (glucose, insu-
lin, insulin resistance index HOMA, lipid profile);
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 — genetic studies to detect the various variants of the 
CNR1 gene.
Anthropometric measurements
Body weight and height were measured on a standard 
beam balance scale with an attached ruler. The waist 
circumference was measured at the umbilicus level 
and hip circumference at the level of the trochanter 
major to the nearest 0.1 cm with a flexible plastic tape. 
The body mass index (BMI) was calculated from the 
equation: weight [kg]/height [m2], and the waist-to-hip 
ratio (WHR) as waist circumference [cm]/hip circumfer-
ence [cm].
Biochemical measurements
Blood for laboratory tests was collected between 8:00 
and 10:00 a.m. after overnight fasting, at least after eight 
hours after the last meal. 
Serum concentrations of glucose, total cholesterol, 
HDL cholesterol, and triglycerides were measured by 
routine enzymatic methods (Dade Behring Marburg 
GmbH, Germany) and LDL cholesterol was calculated 
from Friedewald’s formula: cholesterol LDL [mg/dL] 
= total cholesterol [mg/dL] – HDL cholesterol [mg/ 
/dL] – (triglycerides [mg/dL]/5). 
Serum concentrations of insulin, testosterone, LH, 
FSH, and SHBG were measured by a radio-immuno-
logical method using commercial kits of DPC — Diag-
nostic Products Corporation, Los Angeles, CA, USA. 
The free androgen index (FAI) was calculated from the 
concentrations of total testosterone (T) and SHBG (FAI 
= T/SHBG × 100).
For the estimation of insulin resistance, the HOMA 
insulin resistance index: (insulin (μIU/mL) × glucose 
(mmol/L))/22.5 was computed (I0 — fasting insulin, G0 
— fasting glucose). Subjects were considered as insulin 
resistant when the HOMA index was > 2.5.
Genetic studies
Whole genomic DNA was isolated from blood leu-
kocytes using standard methods. CNR1 genotyping 
(G1422A, A4895G and rs806381, rs10485170, rs6454674, 
rs2023239) was performed by two multiplex polymerase 
chain reactions (PCR) and minisequencing [29].
The first one: three fragments of the CNR1 gene 
(347-bp, 346-bp, and 231-bp) were amplified using 
a multiplex PCR mix containing the specific three 
pairs of primers (Table I), 1× PCR buffer, 1.5 mM 
MgCl2, 200 μM dATP, 200 μM dCTP, 200 μM dGTP, 
200 μM dTTP, 1× Q solution, two polymerase units 
(QIAGEN), 200 ng genomic DNA, and water for 
a total volume of 20 μL.
The DNA was denatured at 95°C for 3 minutes fol-
lowed by 35 cycles of denaturation at 95°C for 30 sec-
onds, annealing at 58°C for 30 seconds, and extension 
at 72°C for 45 seconds. 
To amplify the second group of the four fragments 
of the CNR1 gene (205-bp, 230-bp, 280-bp and 304-bp), 
a multiplex PCR mix was used. It was employed con-
taining the specific four pairs of primers (Table I), 1× PCR 
buffer, 1.5 mM MgCl2 , 200 μM dATP, 200 μM dCTP, 
200 μM dGTP, 200 μM dTTP, two hot-start polymerase 
units (TAKARA), 200 ng genomic DNA, and water for a 
total volume of 20 μL. The DNA was denatured at 95°C 
for 3 minutes followed by 35 cycles of denaturation at 
95°C for 30 seconds, annealing at 56°C for 30 seconds, 
and extension at 72°C for 45 seconds.
The amplified fragments were purified from oligo-
nucleotides and free dNTPs by SAP and ExoI treatment.
The minisequencing method was based on the 
incorporation of single fluorescence-labelled dideoxy-
nucleotides to the 3’ end of the oligonucleotide that 
was correctly paired to the specific template DNA 
fragment using a SNaPshot kit (Applied Biosystems). 
Two SNaPshot reactions were carried out using the 
oligonucleotides: 
 — G1422A: 5’-TGCAGCCAGTGTTCACAGGGCCGCA-
GAAAGCTGCATCAAGAGCAC-3’
 — A4895G: 5’-TTAAGATGCCACGGCAATGTAAA-
GAAACTCTCCCA-3’
 — rs806381: 5’-TCCAACAAATGAGTGACCGTTACC-3’
 — rs10485170: 5’-ACTAGAGTTGTGCTGAGTTAATA-
CATGAGATC-3’
 — rs6454674: 5’-CTTCTCCAAAATATTTCCTG -
GAATAAAAGAAGCAATAACT-3’
 — rs2023239: 5’-GGGTGGGAGTTGAAAGGCAAAA-
GCTAGGTTTGTGGATGTGCCAGGACCA-3’
 — designed so that it ended immediately before the 
polymorphic side. The SNaPshot reaction consisted 
of 25 cycles: denaturation at 96°C for 10 seconds, 
annealing at 50°C for 5 seconds, and extension at 
60°C for 30 seconds. The product was analysed by an 
ABI 3100 sequencer (Applied Biosystems). Product 
size was calculated using GeneScan 4.1 (Applied 
Biosystems).
Statistical analysis
Means and standard deviations of some anthropo-
metric and biochemical parameters were calculated 
for genotypes of the analysed CNR1 polymorphisms. 
To compare means between genotypes, ANOVA was 
used. The level of statistical significance was set at 
p < 0.05.
Results
Anthropometric and metabolic variables according to 
the CNR1 variants are presented in Tables II–VII.
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Table I. Sequences of the CNR1 primers
Tabela I. Sekwencje starterów CNR1
Polymorphism Forward primer (3‘-5‘) Reverse primer (3‘-5‘)
1 G1422A (rs1049353) CCTGCGACACGCTTTCCGGA CTGCCAGGGAGGCATCAGGC
2 A4895G (rs806368) GAGACCACCCATATCATGCACACA AACTCTGATCCCCAGTAGGCCTAG
3 rs806381 CATGAGCCATGAGGTTTTCT CATTTGAAGGCCTGTAACTT
4 rs10485170 TTAACCAATG GTTCATCGTC ATGTGGTTCTCAGGCATCAG
5 rs6454674 ATGGAGCCTGTCCTTTAGGT TATCCAGGAATGCTGCAAAA
6 rs2023239 AATTGAATCCAACCACAGGT AGTTAGGAACTTAGGTGACT
Table II. Anthropometric and metabolic variables according to the A4895G (rs806368) CNR1 polymorphism
Table II. Antropometryczne i metaboliczne zmienne według A4895G (rs806368) polimorfizmu CNR1
G/G A/G A/A p
BMI [kg/m2] PCOS 27.32 ± 7.14 27.04 ± 7.39 26.21 ± 4.95 0.918602
CG 24.89 ± 6.20 26.59 ± 6.31 24.76 ± 4.99 0.579367
WHR PCOS 0.82 ± 0.08 0.81 ± 0.07 0.85 ± 0.08 0.468638
CG 0.80 ± 0.06 0.82 ± 0.07 0.85 ± 0.06 0.180554
Glucose mean [mg/dL] PCOS 86.13 ± 8.14 86.53 ± 10.87 92.43 ± 13.16 0.244467
CG 80.38 ± 8.00 83.14 ± 8.49 83.50 ± 9.47 0.402779
Insulin mean
[μIU/mL]
PCOS 11.17 ± 8.52 9.62 ± 6.48 9.08 ± 3.24 0.547144
CG 8.10 ± 6.01 11.31 ± 9.55 5.85 ± 4.31 0.181982
HOMA PCOS 2.36 ± 1.89 2.11 ± 1.57 2.00 ± 0.79 0.727103
CG 1.62 ± 1.24 2.42 ± 2.39 1.23 ± 0.96 0.161612
TC
[mg/dL]
PCOS 195.78 ± 36.53 193.54 ± 39.15 189.14 ± 23.54 0.879270
CG 179.30 ± 3386 170.62 ± 37.28 174.25 ± 7.37 0.630938
LDL-C
[mg/dL]
PCOS 111.81 ± 31.68 108.22 ± 32.73 121.71 ± 44.82 0.594266
CG 95.71 ± 3069 91.70 ± 30.20 99.50 ± 9.33 0.838456
HDL-C
[mg/dL]
PCOS 60.32 ± 17.87 63.49 ± 15.00 65.57 ± 28.82 0.570079
CG 66.93 ± 17.39 59.57 ± 12.50 57.00 ± 11.69 0.151413
TG
[mg/dL]
PCOS 116.61 ± 72.97 93.92 ± 53.67 119.57 ± 122.50 0.271901
CG 79.76 ± 49.84 91.67 ± 79.49 89.25 ± 51.17 0753350
The total cholesterol and LDL cholesterol levels in 
PCOS women carrying the T/T genotype of rs2023239 
CNR1 polymorphism were higher than in those with 
C/T and C/C. There were no statistical differences in other 
metabolic parameters (HDL cholesterol, triglycerides, 
glucose, insulin and HOMA levels) or in the value of 
BMI and WHR between the variants of rs2023239 CNR1 
polymorphism. No correlations were found between 
the other studied polymorphisms of the CNR1 gene and 
the anthropometric and metabolic parameters in PCOS 
women. There were no differences in anthropometric 
and metabolic parameters between the variants of studied 
polymorphisms of the CNR1 gene in control women. 
Discussion
In recent years, more attention has been paid to the 
endocannabinoid system, which plays an important 
role in energy regulation of several metabolic pathways. 
It participates in food intake, energy balance, lipid 
and glucose metabolism [13–18]. It also influences the 
hypothalamic-pituitary axis by decreasing serum LH 
levels and modulating GnRH secretion. High expres-
sion of endocannabinoids in the ovaries may negatively 
influence ovulation [27, 28]. Taking into account the 
fact that PCOS is the most common endocrinopathy 
in women of reproductive age, and that this syndrome 
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Table III. Anthropometric and metabolic variables according to the A1422G (rs1049353) CNR1 polymorphism
Tabela III. Antropometryczne i metaboliczne zmienne według A1422G (rs1049353) polimorfizmu CNR1
A/G G/G A/A p
BMI [kg/m2] PCOS 27.94 ± 7.43 27.04 ± 6.98 24.86 ± 5.86 0.500137
CG 24.92 ± 6.13 25.98 ± 6.52 24.04 ±4.38 0.659792
WHR PCOS 0.84 ± 0.09 0.81 ± 0.07 0.82 ± 0.07 0.260343
CG 0.81 ± 0.06 0.81 ± 0.06 0.80 ± 0.07 0.976758
Glucose mean
[mg/dL]
PCOS 87.18 ± 8.89 86.68 ± 10.07 84.62 ± 8.19 0.782885
CG 81.38 ± 7.35 81.53 ± 9.15 81.13 ± 6.36 0.991806
Insulin mean
[μIU/mL]
PCOS 10.92 ± 7.55 10.61 ± 8.31 10.45 ± 6.99 0.976230
CG 9.41 ± 5.66 8.80 ± 8.27 8.83 ± 7.23 0.954736
HOMA PCOS 2.39 ± 1.73 2.26 ± 1.89 2.19 ± 1.60 0.924196
CG 1.91 ± 1.24 1.83 ± 1.97 1.81 ± 1.52 0.984544
TC
[mg/dL]
PCOS 197.86 ± 34.03 193.86 ± 36.61 188.00 ± 50.73 0.736143
CG 176.86 ± 37.40 179.08 ± 34.89 161.63 ± 9.30 0,420093
LDL
[mg/dL]
PCOS 114.80 ± 31.46 109.64 ± 32.09 113.12 ± 48.76 0.730545
CG 94.24 ± 30.67 99.78 ± 29.88 72.63 ± 10.07 0.058949
HDL
[mg/dL]
PCOS 61.09 ± 18.20 62.73 ± 17.75 54.37 ± 13.83 0.444302
CG 65.86 ± 17.07 60.71 ± 14.52 75.00 ± 16.11 0.056465
TG
[mg/dL]
PCOS 117.93 ± 69.59 102.89 ± 73.09 112.75 ± 66.92 0.557230
CG 69.76 ± 52.07 94.95 ± 67.55 69.88 ± 25.90 0.239373
Table IV. Anthropometric and metabolic variables according to the rs806381 CNR1 polymorphism
Tabela IV. Antropometryczne i metaboliczne zmienne w zależności od polimorfizmu rs806381 CNR1
G/G A/G A/A p
BMI [kg/m2] PCOS 26.37 ± 6.56 27.015 ± 7.47 27.85 ± 7.97 0.307152
CG 23.57 ± 4,51 25.67 ± 5.76 24.67 ± 6.45 0.698493
WHR PCOS 0.83 ± 0.07 0.82 ± 0.08 0.79 ± 0.08 0.376088
CG 0.79 ± 0.08 0.81 ± 0.06 0.79 ± 0.05 0.406902
Glucose mean
[mg/dL]
PCOS 86.00 ± 7.79 87.31 ± 11.57 85.54 ± 8.12 0.909260
CG 81.80 ± 8.89 80.03 ± 7.87 81.22± 8.37 0.826644
Insulin mean
[μIU/mL]
PCOS 10.27 ± 6.51 10.54 ± 9.23 10.72 ± 7.91 0.997454
CG 8.10 ± 5.90 9.35 ± 6.55 7.49 ± 5.27 0.542649
HOMA PCOS 2.21 ± 1.46 2.29 ± 2.10 2.11 ± 1.74 0.989013
CG 1.67 ± 1.26 1.89 ± 1.44 1.50 ± 1.08 0.556540
TC
[mg/dL]
PCOS 195.22 ± 34.20 194.73 ± 40.05 189.15 ± 36.59 0.956966
CG 163.80 ± 20.63 180.03 ± 36.99 172.04 ± 30.42 0.500047
LDL
[mg/dL]
PCOS 109.51 ± 32.94 114.07 ± 33.63 107.61 ± 37.34 0.899724
CG 86.80 ± 19.18 98.80 ± 28.73 90.26 ± 30.92 0.477881
HDL
[mg/dL]
PCOS 63.87 ± 17.75 59.07 ± 17.90 66.85 ± 18.97 0.408336
CG 59.40 ± 11.67 63.70 ± 15.64 67.35 ± 17.55 0.535297
TG
[mg/dL]
PCOS 105.39 ± 66.69 112.50 ± 84.120 94.23 ± 46.10 0.873601
CG 88.80 ± 45.82 82.73 ± 57.36 71.61 ± 33.29 0.632409
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Table V. Anthropometric and metabolic variables according to the rs10485170 CNR1 polymorphism
Tabela V. Antropometryczne i metaboliczne zmienne w zależności od polimorfizmu CNR1 rs10485170
A/A A/G G/G p
BMI [kg/m2] PCOS 27.48 ± 7.27 24.56 ± 6.50 22.37 ± 2.43 0.206867
CG 25.02 ± 5.79 26.00 ± 6.64 19.29 ± 0.00 0.553472
WHR PCOS 0.82 ± 0.08 0.81 ± 0.07 0.76 ± 0.01 0.533411
CG 0.80 ± 0.06 0.80 ± 0.05 0.81 ± 0.00 0.935797
Glucose mean
[mg/dL]
PCOS 87.13 ± 10.08 84.41 ± 6.95 84.50 ± 4.95 0.541845
CG 81.45 ± 7.99 76.80 ± 7.96 81.45 ± 0.00 0.252519
Insulin mean
[μIU/mL]
PCOS 10.39 ± 6.66 10.69 ± 12.42 7.65 ± 3.46 0.876319
CG 8.13 ±15.93 10.94 ± 6.37 5.10 ± 0.00 0.375709
HOMA PCOS 2.23 ± 1.54 2.27 ± 2.72 1.57 ± 0.63 0.871909
CG 1.67 ± 1.31 2.05 ± 1.24 1.03 ± 0.00 0.630826
TC
[mg/dL]
PCOS 196.58 ± 37.39 181.41 ± 31.03 176.00 ± 31.11 0.236072
CG 179.00 ± 35.61 159.60 ± 14.28 168.00 ± 0.00 0.244641
LDL
[mg/dL]
PCOS 113.78 ± 33.12 97.94 ± 33.01 83.00 ± 0.00 0.146114
CG 97.21 ± 30.21 84.30 ± 19.50 62.00 ± 0.00 0.235718
HDL
[mg/dL]
PCOS 63.30 ± 17.99 57.70 ± 18.28 55.00 ± 0.00 0.470371
CG 65.15 ± 16.19 60.20 ± 13.68 93.00 ± 0.00 0.141430
TG
[mg/dL]
PCOS 102.69 ± 64.37 128.53 ± 101.77 76.00 ± 5.66 0.335585
CG 79.91 ± 52.06 75.20 ± 24.16 65.00 ± 0.00 0.923159
Table VI. Anthropometric and metabolic variables according to the rs6454674 CNR1 polymorphism
Tabela VI. Antropometryczne i metaboliczne zmienne w zależności od polimorfizmu rs6454674 CNR1
T/T G/T G/G p
BMI [kg/m2] PCOS 26.45 ± 6.68 27.72 ± 7.90 26.67 ± 6.45 0.708616
CG 25.03 ± 6.54 25.28 ± 5.58 23.00 ± 3.84 0.870233
WHR PCOS 0.82 ± 0.07 0.81 ± 0.08 0.81 ± 0.09 0.680679
CG 0.79 ± 0.05 0.81 ± 0.07 0.77 ± 0.07 0.351029
Glucose mean
[mg/dL]
PCOS 85.78 ± 7.67 87.55 ± 11.13 88.15 ± 8.79 0.587216
CG 81.32 ± 8.31 80.10 ± 8.11 81.00 ± 5.66 0.854864
Insulin mean
[μIU/mL]
PCOS 9.52 ± 6.54 11.38 ± 9.84 11.84 ± 8.08 0.489187
CG 7.10 ± 5.21 9.85 ± 6.43 4.95 ± 5.99 0.167315
HOMA PCOS 2.04 ± 1.46 2.42 ± 2.27 2.59 ± 1.74 0.519759
CG 1.42 ± 1.06 2.00 ± 1.42 0.96 ± 0.74 0.179625
TC
[mg/dL]
PCOS 196.02 ± 34.75 193.40 ± 42.05 194.77 ± 31.96 0.950608
CG 173.04 ± 29.86 177.35 ± 37.10 176.50 ± 19.09 0.893056
LDL
[mg/dL]
PCOS 111.80 ± 31.88 113.30 ± 36.04 110.92 ± 35.55 0.969192
CG 91.84 ± 30.71 96.42 ± 28.38 94.50 ± 28.93 0.845473
HDL
[mg/dL]
PCOS 63.59 ± 18.03 59.89 ± 19.76 62.54 ± 17.36 0.665642
CG 66.16 ± 17.44 63.58 ± 15.55 66.00 ± 16.09 0.836902
TG
[mg/dL]
PCOS 106.47 ± 80.17 116.05 ± 75.77 102.31 ± 41.82 0.785636
CG 74.68 ± 34.56 82.10 ± 57.89 80.50 ± 19.09 0.850169
187
Endokrynologia Polska 2014; 65 (3)
PR
A
C
E 
O
RY
G
IN
A
LN
E
is related to various metabolic disturbances, we inves-
tigated the effect of six genetic variations in the CNR1 
gene on anthropometric and metabolic parameters in 
130 women with PCOS.
Our study suggests no associations between the 
CNR1 polymorphisms and BMI, WHR and various 
metabolic variables (glucose, insulin, HOMA-IR and 
lipids) in PCOS patients. Only women carrying the T/T 
genotype of rs2023239 CNR1 polymorphism had higher 
total cholesterol and LDL cholesterol levels than those 
with C/T and C/C variants. No correlations were found 
between the other studied CNR1 polymorphisms and 
anthropometric and metabolic parameters in women 
with PCOS. It is worth noting that studied women 
were young (24.91 ± 4.85 years) and were not obese, 
but were overweight (BMI 26.96 ± 6.96 kg/m2). Maybe if 
only obese women had been studied, the results would 
have been different.
To date there have been no studies of CNR1 poly-
morphism in women with PCOS. Similar to our results, 
but in other groups of subjects (German children and 
adolescents), Müller et al. did not find any relation 
between rs2023239 variants and obesity [23]. Lieb et 
al. also found no evidence of an association of CNR1 
genotypes and parameters related to obesity [24]. 
Zhuang et al. investigated rs2023239 and rs806381 poly-
morphisms in Chinese retired women and concluded 
that these variants are not associated with increased 
overweight and obesity risk [25]. In another study, de 
Luis et al. detected no differences in anthropometric 
parameters in patients with obesity and diabetes mel-
litus type 2 and rs1049353 CNR1 polymorphism [26]. 
In our previous studies, we did not observe relations 
between the A3813G (rs12720071), G1422A (rs1049353), 
A4895G (rs806368), rs806381, rs10485170, rs6454674 and 
rs2023239 CNR1 polymorphisms and anthropometric 
measures, or carbohydrate and lipid metabolism in 
postmenopausal women. On the other hand, we noted 
significant associations between the 3813G allele and 
higher android fat deposit and percentage of android 
fat [22, 30].
In contrast to these findings, some studies revealed 
an association between various genetic variants of the 
CNR1 gene and obesity. Peeters et al. observed a rela-
tion between rs1049353 polymorphism (A/A genotype) 
and higher WHR and waist circumference [21]. Russo 
et al. found that subjects with the 12720071G allele had 
higher waist circumference and subscapular skinfold 
thickness [20]. In other studies, Jaeger et al. revealed 
an association between the rs806368G allele and WHR 
[19], and Benzinou et al. reported a relation between 
rs2023239 and rs806381 CNR1 variants and BMI [31]. 
Hu et al. showed that subjects with metabolic syndrome 
and G/A and A/A genotypes of G1359A CNR1 polymor-
Table VII. Anthropometric and metabolic variables according to the rs2023239 CNR1 polymorphism
Tabela VII. Antropometryczne i metaboliczne zmienne w zależności od polimorfizmu rs2023239 CNR1
T/T C/T C/C p
BMI [kg/m2] PCOS 26.90 ± 7.38 28.01 ± 7.31 24.48 ± 5.30 0.568435
CG 24.4 ± 5.09 26.98 ± 7.33 19.29 ± 0.00 0.204006
WHR PCOS 0.82 ± 0.07 0.83 ± 0.09 0.78 ± 0.07 0.254993
CG 0.80 ± 0.06 0.81 ± 0.06 0.81 ± 0.00 0.823443
Glucose mean
[mg/dL]
PCOS 86.10 ± 10.33 88.03 ± 8.91 85.73 ± 6.83 0.747082
CG 81.07 ± 8.20 79.59 ± 8.05 82.00 ± 0.00 0.809505
Insulin mean
[μIU/mL]
PCOS 9.48 ± 6.16 12.25 ± 10.93 11.41 ± 6.94 0.476242
CG 8.16 ± 5.81 9.66 ± 6.61 5.10 ± 0.00 0.598160
HOMA PCOS 2.00 ± 1.45 2.69 ± 2.41 2.43 ± 1.55 0.401481
CG 1,68 ± 1.30 1.87 ± 1.31 1.03 ± 0.00 0.770856
TC
[mg/dL]
PCOS 202.57 ± 38.49 181.50 ± 30.03 179.09 ± 30.11 0.028073
CG 176.47 ± 36.20 173.53 ± 27.43 168.00 ± 0.00 0.932694
LDL
[mg/dL]
PCOS 118.07 ± 32.42 99.60 ± 32.57 101.60 ± 33.89 0.059394
CG 95.55 ± 30.56 93.53 ± 25.20 62.00 ± 0.00 0.521619
HDL
[mg/dL]
PCOS 64.08 ± 18.80 58.33 ± 17.58 60.00 ± 15.81 0.533827
CG 65.47 ± 16.37 61.47 ± 14.35 93.00 ± 0.00 0.144478
TG
[mg/dL]
PCOS 109.10 ± 69.85 117.57 ± 82.22 80.00 ± 61.64 0.473616
CG 73.50 ± 46.38 92.24 ± 51.26 65.00 ± 0.00 0.390350
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phism had lower BMI, waist circumference, HOMA and 
triglycerides [32]. The same results were demonstrated 
by Liu et al. in patients with coronary artery disease 
[33]. Similarly, Wang et al. found a correlation between 
G/G genotype of G1359A and increased values of BMI, 
HOMA and decreased HDL cholesterol level [34].
On the basis of previous studies, as yet there is no 
single, agreed answer to the question as to the rela-
tion between CNR1 polymorphism and obesity and 
related metabolic disturbances. The different results of 
the abovementioned studies may have resulted from 
genetic and phenotypic heterogeneity and differences 
of the studied population (men, women, obese and 
lean people, healthy and with various diseases and 
syndromes, various nationality, various age of subjects). 
Environmental factors, the kind of diet, physical activ-
ity and chronic stress may also influence the results of 
studies in CNR1 polymorphism.
In conclusion, on the basis of our study, it seems that 
CNR1 polymorphisms are not associated with obesity 
and metabolic disorders, including insulin resistance, 
in PCOS women. Further investigations in a larger 
population of women with PCOS need to be performed.
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